AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

2.450

-0.070-2.78%

Volume:326.84K

Turnover:802.89K

Market Cap:199.05M

PE:-2.33

High:2.500

Open:2.480

Low:2.420

Close:2.520

52wk High:7.310

52wk Low:2.420

Shares:81.25M

Float Shares:67.00M

Volume Ratio:0.64

T/O Rate:0.49%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.051

EPS(LYR):-1.186

ROE:-20.58%

ROA:-2.30%

PB:0.56

PE(LYR):-2.07

Loading ...

Overview Company News Filings

Mayne Pharma Group H1 2026 Loss Narrowing Tests Bearish Narratives On Profitability Path

Simply Wall St.

BRIEF-Mayne Pharma Posts H1 Gross Margin 65.3%

Mayne Pharma appoints Aaron Gray CEO as Shawn Patrick O’Brien steps down

Mayne Pharma - Will Continue to Pursue Scale Across Portfolio, Others, Which May Include a Share Buy-Back

THOMSON REUTERS

Mayne Pharma H1 Revenue AUD 212.1 Million

THOMSON REUTERS

Mayne Pharma Group Ltd - Aaron Gray Appointed Chief Executive Officer

THOMSON REUTERS

BRIEF-Mayne Pharma To Claim Against Cosette, Others

Mayne Pharma - Will Commence Proceedings in Supreme Court of New South Wales Against Cosette, Others

THOMSON REUTERS

Mayne Pharma Group Ltd - Seeks Substantial Damages Against Cosette for Breach of Sid, Others

THOMSON REUTERS

Mayne Pharma Group Says Fiscal 2026 H1 Unaudited Revenue Falls 0.5% Year on Year

MT Newswires Live

BRIEF-Mayne Pharma Posts FY A$47M Underlying EBITDA

Mayne Pharma Group Ltd - FY Reported Revenue a$408.1 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd - FY a$47M Underlying Ebitda

THOMSON REUTERS

BRIEF-Australian Government Takeovers Panel Made Orders For Cosette

Australian Govt Takeovers Panel - Made Orders Requiring Cosette to Agree to Any Conditions Reasonably Required by Treasurer

THOMSON REUTERS

BRIEF-Mayne Pharma Receives Notice Of Appeal By Cosette Pharmaceuticals

Mayne Pharma - Received a Notice of Appeal Filed by Cosette and Its Bidco With Supreme Court of New South Wales, Court of Appea

THOMSON REUTERS

Mayne Pharma - Grounds Set Out in Notice of Appeal Seek to Challenge Court's Findings Regarding Co's FY25 Ebitda, Others

THOMSON REUTERS

Mayne Pharma Group Ltd - Considering Notice of Appeal and Intends to Vigorously Defend Appeal

THOMSON REUTERS

BUZZ-Australia's Mayne Pharma hits over 2-year low on board resizing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MYX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":2.45,"timestamp":1772428320000,"preClose":2.52,"halted":0,"volume":326842,"delay":0,"changeRate":-0.027777777777777714,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81245827,"eps":-1.051059,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"03-02 16:12:00 AEDT","open":2.48,"high":2.5,"low":2.42,"amount":802890,"amplitude":0.031746,"askPrice":2.52,"askSize":2233,"bidPrice":2.43,"bidSize":2263,"shortable":3,"etf":0,"ttmEps":-1.051059,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772492400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.52,"openAndCloseTimeList":[[1772406000000,1772427600000]],"volumeRatio":0.644656,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-2.30%","roe":"-20.58%","lyrEps":-1.185711,"volumeRatio":0.644656,"shares":81245827,"dividePrice":0,"high":2.5,"amplitude":0.031746,"preClose":2.52,"low":2.42,"week52Low":2.42,"pbRate":"0.56","psRate":"0.49","week52High":7.31,"institutionHeld":0,"latestPrice":2.45,"committee":0.006673,"eps":-1.051059,"divideRate":0,"volume":326842,"delay":0,"ttmEps":-1.051059,"open":2.48,"prevYearClose":3.11,"prevWeekClose":2.52,"prevMonthClose":2.52,"prevQuarterClose":3.11,"fiveDayClose":2.61,"twentyDayClose":2.69,"sixtyDayClose":3.41,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null},{"date":"2024-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708902000000,"name":null,"time":"","dateTimestamp":1708866000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613158337","title":"Mayne Pharma Group H1 2026 Loss Narrowing Tests Bearish Narratives On Profitability Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2613158337","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613158337?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:39","pubTimestamp":1771922383,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group (ASX:MYX) has released its H1 2026 numbers, posting revenue of A$212.1 million with a basic EPS loss of A$0.15, while trailing 12 month figures show revenue of A$407.1 million and a basic EPS loss of A$1.04. Over recent halves the company has seen revenue sit in the A$195 million to A$213 million range with basic EPS losses between A$0.25 and A$0.89, setting the scene for investors to weigh steady top line scale against ongoing pressure on margins and the path to cleaner...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/mayne-pharma-group-h1-2026-loss-narrowing-tests-bearish-narr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/mayne-pharma-group-h1-2026-loss-narrowing-tests-bearish-narr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2613720854","title":"BRIEF-Mayne Pharma Posts H1 Gross Margin 65.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613720854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613720854?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:09","pubTimestamp":1771812568,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts H1 Gross Margin 65.3%Feb 23 (Reuters) - Mayne Pharma Group Ltd MYX.AX:H1 GROSS MARGIN 65.3%WILL CONTINUE TO PURSUE SCALE ACROSS PORTFOLIO, OTHERS, WHICH MAY INCLUDE A SHARE BUY-BACKFurther company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nPLX32737C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2613272257","title":"Mayne Pharma appoints Aaron Gray CEO as Shawn Patrick O’Brien steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2613272257","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613272257?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:03","pubTimestamp":1771805005,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Limited announced a planned leadership transition, with Shawn Patrick O’Brien stepping down as Chief Executive Officer and Managing Director on 20 February 2026 . Chief Financial Officer Aaron Gray has been appointed CEO, and O’Brien will remain available to the board in an advisory capacity until 1 May 2026 to support the transition. The company has started a formal process to appoint a new CFO, with interim arrangements in place to maintain finance governance and reporting continuity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mayne Pharma Group Limited published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL89R1kc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2613745482","title":"Mayne Pharma - Will Continue to Pursue Scale Across Portfolio, Others, Which May Include a Share Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2613745482","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613745482?lang=en_us&edition=fundamental","pubTime":"2026-02-23 06:35","pubTimestamp":1771799738,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nPLX32737C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2613274592","title":"Mayne Pharma H1 Revenue AUD 212.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613274592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613274592?lang=en_us&edition=fundamental","pubTime":"2026-02-23 06:34","pubTimestamp":1771799686,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nPLX659AA7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2613561274","title":"Mayne Pharma Group Ltd - Aaron Gray Appointed Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613561274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613561274?lang=en_us&edition=fundamental","pubTime":"2026-02-23 06:31","pubTimestamp":1771799491,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nTUE5MFLTZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2612149493","title":"BRIEF-Mayne Pharma To Claim Against Cosette, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2612149493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612149493?lang=en_us&edition=fundamental","pubTime":"2026-02-18 09:15","pubTimestamp":1771377345,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma To Claim Against Cosette, OthersFeb 18  - Mayne Pharma Group Ltd MYX.AX:ASX ALERT-MYX TO CLAIM AGAINST COSETTE, AVISTA & MR DAVID BURGSTAHLERWILL COMMENCE PROCEEDINGS IN SUPREME COURT OF NEW SOUTH WALES AGAINST COSETTE, OTHERSSEEKS SUBSTANTIAL DAMAGES AGAINST COSETTE FOR BREACH OF SID, OTHERSALSO SEEKING SUBSTANTIAL DAMAGES ON ITS OWN BEHALF AGAINST DEFENDANTSFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2612496378","title":"Mayne Pharma - Will Commence Proceedings in Supreme Court of New South Wales Against Cosette, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2612496378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612496378?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:35","pubTimestamp":1771367740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2612496322","title":"Mayne Pharma Group Ltd - Seeks Substantial Damages Against Cosette for Breach of Sid, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2612496322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612496322?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:35","pubTimestamp":1771367740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2607779014","title":"Mayne Pharma Group Says Fiscal 2026 H1 Unaudited Revenue Falls 0.5% Year on Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779014","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779014?lang=en_us&edition=fundamental","pubTime":"2026-01-29 12:03","pubTimestamp":1769659432,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said its unaudited revenue for the fiscal 2026 first half came in at AU$212.1 million, down 0.5% from the result it reported in the year-ago period, according to a Thursday Australian bourse filing.Its unaudited underlying earnings before interest, taxes, depreciation, and amortization  for the period clocked in at AU$28.6 million, down 8% year-over-year from AU$31 million in the first half of fiscal year 2025.It cited a lower contribution from the women's health segment, as well as additional investment into sales activities, as drivers behind the underlying EBIDTA.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2607206547","title":"BRIEF-Mayne Pharma Posts FY A$47M Underlying EBITDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607206547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607206547?lang=en_us&edition=fundamental","pubTime":"2026-01-29 09:22","pubTimestamp":1769649758,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts FY A$47M Underlying EBITDAJan 29 (Reuters) - Mayne Pharma Group Ltd MYX.AX:FY REPORTED REVENUE A$408.1 MILLIONFY A$47M UNDERLYING EBITDAFurther company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT1CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2607729858","title":"Mayne Pharma Group Ltd - FY Reported Revenue a$408.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2607729858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607729858?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:44","pubTimestamp":1769640251,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT1CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2607729853","title":"Mayne Pharma Group Ltd - FY a$47M Underlying Ebitda","url":"https://stock-news.laohu8.com/highlight/detail?id=2607729853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607729853?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:44","pubTimestamp":1769640251,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT1CL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2605039571","title":"BRIEF-Australian Government Takeovers Panel Made Orders For Cosette","url":"https://stock-news.laohu8.com/highlight/detail?id=2605039571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605039571?lang=en_us&edition=fundamental","pubTime":"2026-01-21 18:30","pubTimestamp":1768991420,"startTime":"0","endTime":"0","summary":"BRIEF-Australian Government Takeovers Panel Made Orders For CosetteJan 21 (Reuters) - AUSTRALIAN GOVERNMENT TAKEOVERS PANEL - MADE ORDERS REQUIRING COSETTE TO AGREE TO ANY CONDITIONS REASONABLY REQUIRED BY TREASURERFurther company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YL1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2605173871","title":"Australian Govt Takeovers Panel - Made Orders Requiring Cosette to Agree to Any Conditions Reasonably Required by Treasurer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605173871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605173871?lang=en_us&edition=fundamental","pubTime":"2026-01-21 14:24","pubTimestamp":1768976697,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YL1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2603567824","title":"BRIEF-Mayne Pharma Receives Notice Of Appeal By Cosette Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2603567824","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603567824?lang=en_us&edition=fundamental","pubTime":"2026-01-15 13:12","pubTimestamp":1768453957,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Receives Notice Of Appeal By Cosette PharmaceuticalsJan 15  - Mayne Pharma Group Ltd MYX.AX:RECEIVED A NOTICE OF APPEAL FILED BY COSETTE AND ITS BIDCO WITH SUPREME COURT OF NEW SOUTH WALES, COURT OF APPEALCONSIDERING NOTICE OF APPEAL AND INTENDS TO VIGOROUSLY DEFEND APPEALGROUNDS SET OUT IN NOTICE OF APPEAL SEEK TO CHALLENGE COURT'S FINDINGS REGARDING CO'S FY25 EBITDA, OTHERSFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YF21V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2603678690","title":"Mayne Pharma - Received a Notice of Appeal Filed by Cosette and Its Bidco With Supreme Court of New South Wales, Court of Appea","url":"https://stock-news.laohu8.com/highlight/detail?id=2603678690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603678690?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:55","pubTimestamp":1768452936,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YF21V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2603678611","title":"Mayne Pharma - Grounds Set Out in Notice of Appeal Seek to Challenge Court's Findings Regarding Co's FY25 Ebitda, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2603678611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603678611?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:55","pubTimestamp":1768452936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YF21V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2603618678","title":"Mayne Pharma Group Ltd - Considering Notice of Appeal and Intends to Vigorously Defend Appeal","url":"https://stock-news.laohu8.com/highlight/detail?id=2603618678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603618678?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:55","pubTimestamp":1768452936,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YF21V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2603113650","title":"BUZZ-Australia's Mayne Pharma hits over 2-year low on board resizing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603113650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603113650?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:34","pubTimestamp":1768358052,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma hits over 2-year low on board resizing** Shares of Mayne Pharma MYX.AX slip 1.66% to A$2.96, their lowest since mid-October 2023** Pharma co to cut board's size, says mov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL6N3YF05X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}]}}